Table 3 The comparison between patients with and without treatment limitation
| Â | NIV with treatment limitation (n=19) | NIV without treatment limitation (n=25) | P value (treatment limitation vs. no limitation) | |
|---|---|---|---|---|
| Â | Â | IMV= (n=10) | NIV without treatment limitation (n=15) | Â |
Age | 79(72–85) | 69(67–71) | 70(59–77) | 0.001 |
Gender | 10(53) | 0 | 6(40%) | 0.05 |
Race | 16(84) | 8(80) | 14(93) | 0.77 |
CAD | 11(58) | 6(60) | 7(47) | 0.76 |
Cancer | 8(42) | 3(30) | 6(40) | 0.76 |
Chemotherapy | 4(21) | 3(30) | 1(7) | 0.71 |
CHF | 9(47) | 3(30) | 3(20) | 0.12 |
DM | 8(42) | 3(30) | 7(47) | 0.99 |
Hypertension | 17(89) | 9(90) | 10(67) | 0.43 |
APACHE III score on admission | 54(39–62) | 45(39–63) | 43(23–59) | 0.14 |
ICU length of stay | 2(1–3) | 4(2–9) | 1(1–3) | 0.36 |
Hospital length of stay | 6(3–9) | 7(5–15) | 5(4–8) | 0.39 |
Hospital Mortality | 6(32) | 0 | 0 | 0.008 |
Median survival after Hospital discharge | 43(9–232) | 1341(725–2349) | 1245(815–2472) | <0.001 |